20/20 Biolabs, Inc. (AIDX) IPO — S-1 Filing, Stock & Insider Activity

20/20 Biolabs, Inc. IPO — Status & S-1 Filing

Ticker: AIDX
Status: Effective — cleared to price
S-1 filed: 2025-12-12
Effective: 2026-02-17
Exchange: NASDAQ
Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
Shares offered: 15,130,055
SEC CIK: 0001139685 · View the S-1 on SEC EDGAR →

20/20 Biolabs, Inc. is pre-IPO, so no insider Form 4 transactions have been filed yet. Once insiders begin reporting trades after the offering, they will appear on this page automatically.

Track every registration update on the InsiderAlpha IPO tracker.

Updated Jul 16, 2026 · Last SEC filing 2026-04-06

20/20 Biolabs, Inc. (AIDX) — no SEC Form 4 insider filings recorded in the last 90 days. 4 Form 8-K material event filings were reported by AIDX in the last 90 days. InsiderAlpha tracks every AIDX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About 20/20 Biolabs, Inc. (AIDX)

SEC CIK	0001139685

90-Day SEC Filing Activity

Form 8-K filings (90d)	4
Latest Form 4 filing	2026-04-06

Recent AIDX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-02-19	Rollins John Woodson	Director	J — Other acquisition / disposition	13.0K	$0.00	—	SEC
2026-02-19	Rollins John Woodson	Director	J — Other acquisition / disposition	6.1K	$0.00	—	SEC
2026-02-19	Ross Michael A.	Director	J — Other acquisition / disposition	31	$0.00	—	SEC
2026-02-19	Compton John G.	Director	J — Other acquisition / disposition	7.7K	$0.00	—	SEC
2026-02-19	COHEN RICHARD M	Director	J — Other acquisition / disposition	7.7K	$0.00	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for 20/20 Biolabs, Inc. (AIDX). Updated in real time as new filings are submitted to the SEC.

Recent AIDX Form 8-K Material Events

2026-07-01 — Item 7.01, 9.01 [SEC]
2026-05-26 — Item 3.03, 5.03, 9.01 [SEC]
2026-05-20 — Item 2.02, 9.01 [SEC]
2026-04-28 — Item 1.01, 9.01 [SEC]
2026-03-31 — Item 2.02, 9.01 · Earnings · neutral [SEC]
20/20 Biolabs issued a press release on March 31, 2026 reporting financial results for the year ended December 31, 2025. The filing provides standard annual financial results without explicit beat/miss or guidance language.

Recent Insider Filings

2026-04-06 — Bergman Alan B. (Chief Financial Officer)
2026-04-06 — Zhou Jiming (Chief Operating Officer)
2026-03-04 — Cohen Jonathan M (Chief Executive Officer)
2026-02-24 — Rollins John Woodson (Director)
2026-02-23 — Ross Michael A. (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AIDX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

AIDX Insider Trading — FAQ

What is the latest insider trade for AIDX?: 20/20 Biolabs, Inc. (AIDX) had 0 insider filings in the last 90 days, with the most recent on 2026-04-06. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying AIDX stock?: 0 insider purchases of AIDX were filed in the last 90 days.
How many insiders are selling AIDX stock?: 0 insider sales of AIDX were filed in the last 90 days.
Where can I see AIDX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every AIDX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live AIDX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.